Equities Analysts Offer Predictions for SLDB Q1 Earnings

Solid Biosciences Inc. (NASDAQ:SLDB) – Stock analysts at HC Wainwright upped their Q1 2025 earnings estimates for Solid Biosciences in a research report issued on Monday, March 10th. HC Wainwright analyst A. He now forecasts that the company will post earnings of ($0.43) per share for the quarter, up from their prior forecast of ($0.86). HC Wainwright has a “Buy” rating and a $20.00 price target on the stock. The consensus estimate for Solid Biosciences’ current full-year earnings is ($2.84) per share. HC Wainwright also issued estimates for Solid Biosciences’ Q2 2025 earnings at ($0.44) EPS, Q3 2025 earnings at ($0.44) EPS, Q4 2025 earnings at ($0.45) EPS, FY2025 earnings at ($1.76) EPS, FY2026 earnings at ($1.99) EPS, FY2027 earnings at ($1.73) EPS, FY2028 earnings at ($0.77) EPS and FY2029 earnings at $1.14 EPS.

Several other equities analysts have also weighed in on the company. Truist Financial began coverage on Solid Biosciences in a research note on Wednesday, January 8th. They issued a “buy” rating and a $16.00 price target for the company. Chardan Capital reaffirmed a “buy” rating and set a $16.00 target price on shares of Solid Biosciences in a research note on Friday, March 7th. Wedbush initiated coverage on Solid Biosciences in a research report on Friday, December 13th. They set an “outperform” rating and a $16.00 target price on the stock. JMP Securities initiated coverage on shares of Solid Biosciences in a research report on Tuesday, December 10th. They set an “outperform” rating and a $15.00 price objective for the company. Finally, Citizens Jmp raised shares of Solid Biosciences to a “strong-buy” rating in a research note on Tuesday, December 10th. Nine equities research analysts have rated the stock with a buy rating and four have given a strong buy rating to the company’s stock. Based on data from MarketBeat.com, the stock has an average rating of “Buy” and an average target price of $15.80.

Solid Biosciences Stock Up 2.1 %

Shares of SLDB opened at $5.73 on Wednesday. The company has a market capitalization of $437.31 million, a price-to-earnings ratio of -1.88 and a beta of 1.98. Solid Biosciences has a 52 week low of $2.88 and a 52 week high of $15.05. The stock’s 50-day moving average price is $4.12 and its 200-day moving average price is $5.47.

Institutional Trading of Solid Biosciences

A number of hedge funds and other institutional investors have recently modified their holdings of the business. Los Angeles Capital Management LLC acquired a new position in shares of Solid Biosciences in the 3rd quarter worth approximately $293,000. Valence8 US LP acquired a new stake in shares of Solid Biosciences in the third quarter valued at $110,000. The Manufacturers Life Insurance Company purchased a new stake in shares of Solid Biosciences in the 3rd quarter valued at $71,000. FMR LLC acquired a new position in Solid Biosciences during the 3rd quarter worth about $305,000. Finally, MetLife Investment Management LLC lifted its stake in Solid Biosciences by 129.1% during the 3rd quarter. MetLife Investment Management LLC now owns 13,699 shares of the company’s stock worth $95,000 after acquiring an additional 7,719 shares in the last quarter. 81.46% of the stock is owned by institutional investors and hedge funds.

Solid Biosciences Company Profile

Solid Biosciences Inc, a life science company, develops therapies for neuromuscular and cardiac diseases in the United States. The company's lead product candidate is SGT-003, a gene transfer candidate for the treatment of Duchenne muscular dystrophy; and SGT-501 to treat Catecholaminergic polymorphic ventricular tachycardia.